×

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018

OXFORD, United Kingdom and CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the fourth quarter and fiscal year ended 31 January 2018 on 11 April 2018.

Summit will host a conference call and webcast the same day to discuss its operational progress at 1:00pm BST / 8:00am EDT. Conference call and webcast information will be included in the full year results press release. A replay of the call will also be available through the Company's website, www.summitplc.com, shortly after its conclusion.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)Tel:+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
Panmure Gordon (Joint Broker)Tel:+44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
Tom Salvesen, Corporate Broking
MacDougall Biomedical Communications (US)Tel:+1 781 235 3060
Karen Sharma ksharma@macbiocom.com
Consilium Strategic Communications (UK)Tel:+44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson / summit@consilium-comms.com
Philippa Gardner / Rosie Phillips

-END-

Source:Summit Therapeutics plc